Holdings Ltd.Dexcel Pharma ... Net Worth

The estimated Net Worth of Holdings Ltd.Dexcel Pharma ... is at least $247 Milion dollars as of 17 June 2019. Holdings Pharma owns over 18,204 units of Urovant Sciences Ltd stock worth over $247,116,741 and over the last 7 years Holdings sold UROV stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Holdings Pharma UROV stock SEC Form 4 insiders trading

Holdings has made over 19 trades of the Urovant Sciences Ltd stock since 2018, according to the Form 4 filled with the SEC. Most recently Holdings bought 18,204 units of UROV stock worth $151,457 on 17 June 2019.

The largest trade Holdings's ever made was buying 14,285,714 units of Urovant Sciences Ltd stock on 5 June 2018 worth over $25,000,000. On average, Holdings trades about 2,844,747 units every 18 days since 2017. As of 17 June 2019 Holdings still owns at least 22,860,013 units of Urovant Sciences Ltd stock.

You can see the complete history of Holdings Pharma stock trades at the bottom of the page.

Insiders trading at Urovant Sciences Ltd

Over the last 6 years, insiders at Urovant Sciences Ltd have traded over $0 worth of Urovant Sciences Ltd stock and bought 22,782,569 units worth $411,146,115 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... oraz Andrew Lo. On average, Urovant Sciences Ltd executives and independent directors trade stock every 6 days with the average trade being worth of $6,293,420. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 19 February 2020, trading 103,250 units of UROV stock currently worth $1,350,510.

What does Urovant Sciences Ltd do?

Complete history of Holdings Pharma stock trades at Arbutus Biopharma Corp, Myovant Sciences Ltd oraz Urovant Sciences Ltd

Urovant Sciences Ltd executives and stock owners

Urovant Sciences Ltd executives and other stock owners filed with the SEC include:

• Cornelia Haag-Molkenteller,
  Chief Medical Officer of USI
• Bryan Smith,
  General Counsel - USI
• Michael McFadden,
  Chief Commercial Officer
• Christine Ocampo,
  Senior Vice President, Chief Accounting Officer, Principal Accounting Officer
• Kenton Stewart,
  Senior Vice President of Market Access
• Walt Johnston,
  Senior Vice President of Commercial
• James Hindman,
  Director
• Shigeyuki Nishinaka,
  Director
• Ajay Bansal,
  Chief Financial Officer, Senior Vice President - Business Development, Principal Financial Officer
• Myrtle Potter,
  Chairman of the Board
• James Robinson,
  Principal Executive Officer, Director
• Pierre Legault,
  Independent Director
• Sef Kurstjens,
  Independent Director
• Holdings Ltd.Dexcel Pharma ...,
  
• Associates Gp Llcqvt Fund V...,
  
• Patrick Machado,
  
• Frank Torti,
  Director
• Global Investors Lp Viking ...,
  
• Investments (Uk) Ltd Soft B...,
  
• Nori Ebersole,
  SVP&CHRO-Urovant Sciences,Inc.
• Global Performance Llc Viki...,
  
• Sciences Ltd. Roivant,
  10% owner
• Andrew Lo,
  
• Global Performance Llc Viki...,
  
• Associates Gp Llcqvt Financ...,
  
• Chemical Co., Ltd.Sumitomo ...,
  
• Keith Katkin,
  PEO;CEO/Urovant Sciences, Inc.